{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-029370","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.663658+00:00","generated_at":"2026-05-24T03:10:53.627840+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement","bullets":["Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.","Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.","Company cautions no assurance that plan will be accepted or compliance regained."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-029370","json":"https://secwatch.observer/filing/0001104659-25-029370.json","markdown":"https://secwatch.observer/filing/0001104659-25-029370.md","text":"https://secwatch.observer/filing/0001104659-25-029370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/0001104659-25-029370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/tm2510590d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:10:53.627840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}